Pluri Inc. (TLV: PLUR)

Market Cap	107.00M
Revenue (ttm)	1.26M
Net Income (ttm)	-79.81M
Shares Out	n/a
EPS (ttm)	-15.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,232
Open	1,940.00
Previous Close	1,940.00
Day's Range	1,924.00 - 1,962.00
52-Week Range	1,776.00 - 2,900.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 12, 2024

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company’s development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta tha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 134
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: PLUR

Financial Performance

In 2023, Pluri's revenue was $287,000, an increase of 22.65% compared to the previous year's $234,000. Losses were -$28.32 million, -31.33% less than in 2022.

Financial numbers in USD